COMPRO Drug Patent Profile
When do Compro patents expire, and when can generic versions of Compro launch?
Compro is a drug marketed by Padagis Us and is included in one NDA.
The generic ingredient in COMPRO is prochlorperazine. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the prochlorperazine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Compro
A generic version of COMPRO was approved as prochlorperazine by COSETTE PHARMS NC on November 24th, 1993.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for COMPRO?
- What are the global sales for COMPRO?
- What is Average Wholesale Price for COMPRO?
Summary for COMPRO
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 48 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,650 |
| Drug Prices: | Drug price information for COMPRO |
| DailyMed Link: | COMPRO at DailyMed |
Recent Clinical Trials for COMPRO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Stony Brook University | Phase 4 |
Pharmacology for COMPRO
| Drug Class | Phenothiazine |
US Patents and Regulatory Information for COMPRO
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | COMPRO | prochlorperazine | SUPPOSITORY;RECTAL | 040246-001 | Jun 28, 2000 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
